Ardelyx, Inc. (ARDX) - What Are Brokerages Saying About This Stock?

Key Points

• Analysts lean bullish: Twelve brokerages give Ardelyx a “Moderate Buy” consensus, with eight Buy and two Strong Buy ratings; the average one-year price target is $13.60.
• Recent analyst actions were mixed but mostly positive: HC Wainwright reaffirmed Buy at a $13 target, while Piper Sandler cut its target to $15 but kept an Overweight rating; Citigroup lowered its target to $11 and maintained Buy.
• Risks include ongoing securities litigation alleging misleading sales projections, as well as unusually high put-option trading. The allegations have not been established as fact.

Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twelve brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $13.60.

A number of equities analysts have recently commented on the company. HC Wainwright reaffirmed a "buy" rating and issued a $13.00 price target on shares of Ardelyx in a report on Friday, August 7th. Piper Sandler decreased their price objective on Ardelyx from $16.00 to $15.00 and set an "overweight" rating on the stock in a research note on Monday, August 17th. Wedbush reissued an "outperform" rating and set a $9.00 price objective on shares of Ardelyx in a report on Tuesday, August 18th. Citigroup dropped their price objective on Ardelyx from $14.00 to $11.00 and set a "buy" rating on the stock in a report on Monday, August 10th. Finally, TD Cowen started coverage on Ardelyx in a research note on Wednesday, November 4th. They issued a "strong-buy" rating for the company.

Ardelyx Stock Up 4.0%

Ardelyx stock opened at $3.13 on Thursday. The firm has a 50 day simple moving average of $3.30 and a 200 day simple moving average of $5.16. The company has a current ratio of 3.45, a quick ratio of 3.26 and a debt-to-equity ratio of 1.54. Ardelyx has a 1-year low of $2.80 and a 1-year high of $8.40. The firm has a market capitalization of $786.79 million, a price-to-earnings ratio of -14.23 and a beta of 0.79.

Insider Activity

In other news, insider Eric Foster sold 8,562 shares of the firm's stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $3.86, for a total value of $33,049.32. Following the completion of the transaction, the insider directly owned 409,410 shares in the company, valued at approximately $1,580,322.60. This trade represents a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider James Brady sold 15,136 shares of the business's stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $3.86, for a total transaction of $58,424.96. Following the transaction, the insider directly owned 245,930 shares of the company's stock, valued at approximately $949,289.80. This represents a 5.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 126,059 shares of company stock valued at $486,588. 5.30% of the stock is currently owned by insiders.

Institutional Trading of Ardelyx

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Principal Financial Group Inc. boosted its holdings in Ardelyx by 22.7% in the 1st quarter. Principal Financial Group Inc. now owns 17,570 shares of the biopharmaceutical company's stock valued at $105,000 after purchasing an additional 3,253 shares during the period. NewEdge Advisors LLC increased its holdings in shares of Ardelyx by 30.0% in the second quarter. NewEdge Advisors LLC now owns 23,724 shares of the biopharmaceutical company's stock worth $121,000 after purchasing an additional 5,476 shares during the period. Swiss National Bank raised its position in shares of Ardelyx by 1.2% in the first quarter. Swiss National Bank now owns 480,800 shares of the biopharmaceutical company's stock worth $2,880,000 after buying an additional 5,600 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Ardelyx by 15.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 45,467 shares of the biopharmaceutical company's stock worth $154,000 after buying an additional 6,152 shares in the last quarter. Finally, Profund Advisors LLC raised its position in shares of Ardelyx by 6.1% in the third quarter. Profund Advisors LLC now owns 111,771 shares of the biopharmaceutical company's stock worth $382,000 after buying an additional 6,433 shares in the last quarter. Institutional investors own 58.92% of the company's stock.

Ardelyx News Summary

Here's some of the latest news about ARDX:

• Neutral Sentiment: Ardelyx plans to participate in a fireside chat at the Jefferies Global Healthcare Conference on November 17. The event could provide an opportunity for updates, but no new business information was announced. Ardelyx conference announcement
• Negative Sentiment: Several law firms are publicizing the November 16 lead-plaintiff deadline for an existing securities class action covering investors who bought shares between January 2025 and August 2026. The complaint alleges Ardelyx executives made sales projections for XPHOZAH and IBSRELA while payer-access barriers were developing. These are allegations, not established findings, but the litigation creates uncertainty and potential reputational and financial risks. Class-action notice and allegations
• Negative Sentiment: Traders bought about 20,015 ARDX put options, roughly 466% above the typical volume. The spike may reflect increased demand for downside protection or bearish positioning, though options activity alone does not establish the market’s outlook.

About Ardelyx

Ardelyx, Inc. is a biopharmaceutical company that develops and commercializes medicines for kidney and gastrointestinal diseases. Founded in 2007, the company has focused on treatments that work in the gastrointestinal tract, including therapies based on tenapanor. Ardelyx markets IBSRELA (tenapanor) in the United States for adults with irritable bowel syndrome with constipation. It also markets XPHOZAH (tenapanor) to help control serum phosphorus in adults with chronic kidney disease who are on dialysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.